Filing Details
- Accession Number:
- 0000899243-21-010517
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-03-08 21:09:02
- Reporting Period:
- 2021-03-04
- Accepted Time:
- 2021-03-08 21:09:02
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1521036 | Lantheus Holdings Inc. | LNTH | In Vitro & In Vivo Diagnostic Substances (2835) | 352318913 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1801395 | Paul Blanchfield | C/O Lantheus Holdings, Inc. 331 Treble Cove Road North Billerica MA 01862 | Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2021-03-04 | 4,061 | $18.40 | 26,509 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-03-04 | 33,820 | $0.00 | 60,329 | No | 4 | A | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | A | Direct |
Footnotes
- The Company requires certain senior executives to cover tax liabilities resulting from the vesting of their equity awards pursuant to sell-to-cover transactions in compliance with Rule 10b5-1. The transactions reported in this Form 4 were effected in compliance with Rule 10b5-1 to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4.
- Includes 1,570 shares acquired under the LNTH employee stock purchase plan on September 11, 2020.
Billionaire Hedge Funds
